TG Therapeutics Raises 2026 Revenue Target to About $1 Billion

The Tip Desk · November 9, 2026 · 4 min read

Third-quarter global revenue was $259.9 million as BRIUMVI U.S. net product sales reached $232.6 million.

TG Therapeutics, Inc. (TGTX), a commercial-stage biotechnology company focused on B-cell diseases, raised its full-year 2026 total global revenue target to approximately $1 billion from approximately $950 million after another quarter of BRIUMVI growth.

The company also lifted its full-year 2026 BRIUMVI U.S. net product revenue target to approximately $915 million to $920 million from $890 million to $905 million. Chairman and Chief Executive Officer Michael S. Weiss said the company is on track to exceed $1 billion in global revenue in 2026, less than four years after launching BRIUMVI, with a strong fourth quarter anticipated.

Total global revenue was $259.9 million in the third quarter of 2026, up from $240.3 million in the second quarter. BRIUMVI U.S. net product revenue was $232.6 million, representing approximately a 52% increase over the same period last year. That year-over-year growth rate slowed from approximately 64% in the second quarter.

Product revenue, net was $240.0 million for the three months ended September 30, 2026, compared with $159.3 million a year earlier. U.S. BRIUMVI net product sales totaled $232.6 million in that quarter. Sales to ex-U.S. licensing partner Neuraxpharm were $7.4 million. License, milestone, royalty and other revenue was approximately $19.9 million, versus approximately $2.4 million a year earlier, predominantly from royalty and commercialization-agreement items with the ex-U.S. partner.

Operating income was $85.9 million in the third quarter, versus $29.4 million a year earlier. Net income was $55.5 million, or $0.35 a share on a diluted basis, compared with net income of $390.9 million, or $2.43 a share, a year earlier, when a non-recurring income tax benefit of approximately $365.0 million from a deferred tax asset valuation allowance release was included.

Research and development expense was approximately $51.3 million in the third quarter, versus $40.9 million a year earlier. The company said the increase was primarily attributable to subcutaneous manufacturing and secondary manufacturer expenses, as well as clinical trial-related expenses. Selling, general and administrative expense was approximately $80.7 million, versus $63.4 million a year earlier, primarily due to higher marketing and media spend and personnel costs associated with BRIUMVI commercialization.

Cash, cash equivalents and investment securities were $556.7 million as of September 30, 2026, versus $199.5 million at December 31, 2025. The company said it anticipates that cash as of September 30, 2026, combined with projected BRIUMVI revenues, will be sufficient to fund the business based on its current operating plan.

TG Therapeutics repurchased approximately $100 million of common stock in the third quarter, about 2.0 million shares at an average price of $49.43. Through the end of the quarter, cumulative repurchases totaled $300 million, or 8.9 million shares, about 6% of shares outstanding, at an average price of $33.88. The company said the approximately $100 million of shares repurchased during the quarter underscores its confidence in long-term value.

Full-year 2026 operating expense guidance of approximately $450 million to $500 million, excluding non-cash compensation and including subcutaneous BRIUMVI manufacturing and secondary manufacturer start-up costs, was reaffirmed.

At MSToronto2026, the company presented Phase 3 ENHANCE results showing bioequivalent drug exposure between the approved two-infusion initiation regimen and a consolidated single 600 mg infusion, with comparable infusion-related reactions and no Grade 3 or higher reactions. Phase 1 subcutaneous BRIUMVI data showed mean bioavailability greater than 60% relative to IV administration, with pharmacokinetic modeling supporting the quarterly dosing regimen in the fully enrolled Phase 3 trial. Top-line Phase 3 data are expected by year-end 2026 or early 2027. Seven-year ULTIMATE I and II follow-up showed an annualized relapse rate of 0.018 in the seventh year and 88.3% of continuously treated patients remaining free from 24-week confirmed disability progression.

Weiss said catalysts over the next 18 to 24 months include those Phase 3 subcutaneous results, a potential launch of simplified IV initiation in mid-2027, additional pipeline data, and a potential subcutaneous BRIUMVI launch in 2028. The company also initiated a potentially registration-directed Phase 2 trial of IV BRIUMVI as maintenance therapy after efgartigimod induction in myasthenia gravis and a Phase 2 trial in treatment-resistant schizophrenia.